Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Launched by BEIJING TIANTAN HOSPITAL · Nov 6, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at whether hydrocortisone, a medication that helps manage hormone levels, can reduce the risk of adrenal insufficiency in patients with large pituitary neuroendocrine tumors. Adrenal insufficiency is a condition where the body doesn’t produce enough hormones from the adrenal glands, which can lead to serious health issues. Participants in the trial will receive either hydrocortisone or a placebo (a substance that looks like the drug but has no active ingredients) daily for two weeks after their surgery. They will also keep a diary of their symptoms and return to the clinic for check-ups three months later.

To be eligible for this trial, patients should be between 18 and 70 years old and have a specific type of pituitary tumor that can be treated with a certain type of surgery. The tumor must be at least 2 centimeters in size, and patients should not have a history of certain hormone-related conditions. The trial is currently recruiting participants of all genders. If you or a loved one are considering joining, you would have the chance to help researchers understand the role of hydrocortisone in managing hormone health after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Age range: 18-70 years old;
• • (2) Accept PitNETs patients who can be treated with endoscopic transsphenoidal surgery;
• • (3) The maximum diameter of the tumor is ≥ 2 centimeters;
• • (4) Preoperative hypothalamic pituitary adrenal axis integrity;
• • (5) The subject or their legal representative signs the informed consent form
• Exclusion Criteria:
• • (1) Patients with a history of Cushing's disease or adrenal insufficiency;
• • (2) Emergency and combined hormone therapy patients;
• • (3) Pituitary stroke patients;
• • (4) Patients lacking head magnetic resonance imaging;